{ "id": "ep1kf81mp1", "slug": "substance-abuse-detection", "title": "Substance abuse detection", "updated": "2026-09-30", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical" }, { "id": "life.health.clinical.clinical-diagnostics", "label": "Diagnosis and clinical assessment", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-diagnostics" }, { "id": "life.health.clinical.clinical-diagnostics.exercise-and-functional-performance-testing", "label": "Exercise and functional performance testing", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-diagnostics.exercise-and-functional-performance-testing" } ], "geo": [ { "id": "geo.nongeo.t1946.life.health.clinical.clinical-diagnostics", "label": "Non-geographic · 1946 to 2000: Diagnosis and clinical assessment", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-diagnostics", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t1946", "label": "Non-geographic · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946" }, { "id": "geo.nongeo.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life" }, { "id": "geo.nongeo.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health" }, { "id": "geo.nongeo.t1946.life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical" }, { "id": "geo.nongeo.t1946.life.health.clinical.clinical-diagnostics", "label": "Diagnosis and clinical assessment", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-diagnostics" } ] } ], "excerpt": "Substance abuse detection, also called drug abuse screening, is the set of clinical methods for identifying drug or alcohol misuse through questionnaires, laboratory testing, and electronic health record analysis.", "snippet": "Substance abuse detection, also called drug abuse screening, is the set of clinical methods for identifying drug or alcohol misuse through questionnaires, laboratory testing, and electronic health record analysis.", "node": "life.health.clinical.clinical-diagnostics.exercise-and-functional-performance-testing", "markdown": "# Substance abuse detection\n\nSubstance abuse detection is the set of clinical methods used to identify drug or alcohol misuse: self-report questionnaires, laboratory testing of biological specimens, and, more recently, analysis of electronic health records. Screening of any kind produces a positive or negative screen or a risk flag, not a diagnosis; a substance use disorder diagnosis is made by clinical interview against DSM-5-TR criteria.[1](https://jamanetwork.com/journals/jama/fullarticle/2766873) • [2](https://www.ncbi.nlm.nih.gov/books/NBK565474/) The USPSTF defines screening as asking one or more questions about drug use or drug-related risks, explicitly excluding testing of urine, saliva, blood, or other specimens.[1](https://jamanetwork.com/journals/jama/fullarticle/2766873) Most clinical programs organize detection within the SBIRT model: universal screening, brief intervention for positive screens, and referral to treatment, which is indicated for only about 5% of people screened.[3](https://health.maryland.gov/pophealth/Documents/Local%20Health%20Department%20Billing%20Manual/PDF%20Manual/Section%20IV/SBIRT%20Toolkit.pdf)\n\n| Key fact | Detail |\n|---|---|\n| Output of screening | A positive or negative screen or risk flag; diagnosis requires a DSM-5-TR clinical interview[1](https://jamanetwork.com/journals/jama/fullarticle/2766873) • [2](https://www.ncbi.nlm.nih.gov/books/NBK565474/) |\n| AUDIT | 10 items scored 0–4 (maximum 40); a score of 8 or more is a positive screen, 20 or more suggests dependence[4](https://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.1993.tb02093.x) • [5](https://www.uptodate.com/contents/screening-for-unhealthy-use-of-alcohol-and-other-drugs-in-primary-care/print) |\n| CAGE | 4 items; two affirmative answers are 77% sensitive and 79% specific for alcohol use disorder[6](https://jamanetwork.com/journals/jama/fullarticle/394693) • [5](https://www.uptodate.com/contents/screening-for-unhealthy-use-of-alcohol-and-other-drugs-in-primary-care/print) |\n| Urine detection windows | 1–3 days after a small dose; up to 3 months for cannabinoids after heavy chronic use (one review gives 30 days)[7](https://www.ncbi.nlm.nih.gov/books/NBK557523/) • [8](https://www.mayoclinicproceedings.org/article/s0025-6196%2811%2961120-8/fulltext) |\n| Test hierarchy | Presumptive immunoassay first; gas or liquid chromatography with mass spectrometry is the definitive (confirmatory) method[8](https://www.mayoclinicproceedings.org/article/s0025-6196%2811%2961120-8/fulltext) • [9](https://myadlm.org/Science-and-Research/Academy-Guidance/Testing-for-Drugs-of-Misuse-to-Support-the-Emergency-Department) |\n| Questionnaire accuracy | Sensitivity 0.71–0.94 and specificity 0.87–0.97 for unhealthy use of any drug; positive predictive value approximately 40% at 11% adult prevalence[10](https://www.uspreventiveservicestaskforce.org/home/getfilebytoken/R3y9LSud52CGL8mG4wvxoT) |\n| USPSTF recommendation | Screen adults 18 and older (B recommendation) when diagnosis and treatment can be offered; insufficient evidence for adolescents[1](https://jamanetwork.com/journals/jama/fullarticle/2766873) |\n\n## How it works\n\nThe three routes detect different things. Questionnaires measure self-reported consumption and consequences, so they can flag hazardous use long before a drug is detectable in the body. Laboratory testing detects the drug or its metabolites directly: immunoassays use antibodies that bind a target drug or metabolite, and a specimen is called positive when the signal reaches a calibrated cutoff concentration.[8](https://www.mayoclinicproceedings.org/article/s0025-6196%2811%2961120-8/fulltext) Cutoffs are concentration thresholds specified for particular analytes and testing programs, and immunoassay sensitivity, specificity, and confirmation rates vary by assay and population rather than being guaranteed by the cutoff.[11](https://library.samhsa.gov/sites/default/files/sma12-4668.pdf) • [33](https://www.federalregister.gov/documents/2025/01/16/2025-00425/mandatory-guidelines-for-federal-workplace-drug-testing-programs-authorized-testing-panels) Point-of-care cups use a competitive lateral-flow immunoassay read visually: a negative result shows two lines (test and control) and a positive result shows only the control line, within 5–10 minutes of collection.[12](https://jlpm.amegroups.org/article/view/10561/html)\n\n## How it is done\n\n**Questionnaires.** CAGE asks four yes/no questions about Cutting down, Annoyance by criticism, Guilty feelings, and Eye-openers.[6](https://jamanetwork.com/journals/jama/fullarticle/394693) AUDIT covers consumption, drinking behavior, and alcohol-related problems in 10 items scored 0–4; 92% of people diagnosed with hazardous or harmful use scored 8 or more, and 94% of non-hazardous drinkers scored below 8.[4](https://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.1993.tb02093.x) A score of 8 or more is more than 90% sensitive and 80% specific for unhealthy alcohol use, and 20 or more suggests dependence.[5](https://www.uptodate.com/contents/screening-for-unhealthy-use-of-alcohol-and-other-drugs-in-primary-care/print) The three-item AUDIT-C is a consumption-only brief version.[13](https://doi.org/10.1001/archinte.158.16.1789) Single-item screens ask about heavy drinking days (five or more drinks for men, four for women and men over 65; one or more is positive) and about any illegal drug or non-medical prescription use in the past year; a response above zero is 100% sensitive and 74% specific for a drug use disorder.[3](https://health.maryland.gov/pophealth/Documents/Local%20Health%20Department%20Billing%20Manual/PDF%20Manual/Section%20IV/SBIRT%20Toolkit.pdf) • [5](https://www.uptodate.com/contents/screening-for-unhealthy-use-of-alcohol-and-other-drugs-in-primary-care/print) DAST-10 covers all drug use in 10 items but does not identify drug classes.[14](https://doi.org/10.1016/0306-4603%2882%2990005-3) • [2](https://www.ncbi.nlm.nih.gov/books/NBK565474/) ASSIST covers all psychoactive substances; in emergency departments a threshold of 18 showed 90% sensitivity and 87% specificity for illicit substance abuse or dependence.[15](https://doi.org/10.1046/j.1360-0443.2002.00185.x) • [16](https://intjem.biomedcentral.com/articles/10.1186/s12245-024-00616-2) The TAPS Tool is a two-step instrument: TAPS-1 is a 4-item screen for tobacco, alcohol, illicit drugs, and non-medical prescription drug use, and any answer other than \"never\" leads to the TAPS-2 brief assessment.[17](https://nida.nih.gov/taps2)\n\n**Laboratory testing.** Urine is the preferred matrix for most US laboratories because of assay availability, higher drug concentrations, and ease of collection; oral fluid allows witnessed, noninvasive collection but has higher false-negative rates.[9](https://myadlm.org/Science-and-Research/Academy-Guidance/Testing-for-Drugs-of-Misuse-to-Support-the-Emergency-Department) Urine, blood, breath, saliva, sweat, nails, hair, and meconium (for neonates) are all used matrices.[7](https://www.ncbi.nlm.nih.gov/books/NBK557523/) • [11](https://library.samhsa.gov/sites/default/files/sma12-4668.pdf) Specimen validity is checked with pH, temperature, creatinine, and specific gravity; creatinine below 20 mg/dL indicates dilute urine, and values of pH below 3 or above 11 or specific gravity below 1.002 or above 1.030 suggest adulteration or dilution.[8](https://www.mayoclinicproceedings.org/article/s0025-6196%2811%2961120-8/fulltext) • [18](https://www.mayoclinicproceedings.org/article/S0025-61961630825-4/fulltext) A positive or disputed immunoassay is confirmed by gas or liquid chromatography coupled to mass spectrometry, which identifies specific molecular structures and quantifies the drug.[8](https://www.mayoclinicproceedings.org/article/s0025-6196%2811%2961120-8/fulltext) • [9](https://myadlm.org/Science-and-Research/Academy-Guidance/Testing-for-Drugs-of-Misuse-to-Support-the-Emergency-Department)\n\n## Origin\n\nThe [CAGE questionnaire](https://www.edgepedia.org/cage-questionnaire) was validated by Mayfield, McLeod, and Hall in the American Journal of Psychiatry in 1974.[19](https://doi.org/10.1176/ajp.131.10.1121) AUDIT was published in [Addiction](https://www.edgepedia.org/addiction).[4](https://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.1993.tb02093.x) Skinner published the Drug Abuse Screening Test in 1982,[14](https://doi.org/10.1016/0306-4603%2882%2990005-3) the AUDIT-C appeared in a 1998 Archives of Internal Medicine paper by Kristen Bush,[13](https://doi.org/10.1001/archinte.158.16.1789) Cherpitel published the Rapid Alcohol Problems Screen for emergency rooms in 1995,[20](https://doi.org/10.1016/0376-8716%2895%2901199-4) and the WHO ASSIST Working Group published ASSIST in 2002.[15](https://doi.org/10.1046/j.1360-0443.2002.00185.x) The TAPS Tool was validated by McNeely and colleagues in a 2016 multisite primary care study of 2,000 patients.[21](https://doi.org/10.7326/m16-0317) The SMART-AI deep learning algorithm for substance misuse was published by Afshar and colleagues in 2022.[22](https://doi.org/10.1016/s2589-7500%2822%2900041-3)\n\n## Variants\n\n**Brief screening versus comprehensive assessment.** SBIRT-style programs use a two-step design: a very short screen (single items, AUDIT-C, TAPS-1) followed by a fuller instrument (full AUDIT, DAST-10, TAPS-2, ASSIST) for positive screens.[3](https://health.maryland.gov/pophealth/Documents/Local%20Health%20Department%20Billing%20Manual/PDF%20Manual/Section%20IV/SBIRT%20Toolkit.pdf) ASAM promotes \"smarter\" drug testing: more frequent random testing, matrices matched to the assessment (blood, oral fluid, hair), and rotating broad panels rather than the fixed five-drug workplace panel.[7](https://www.ncbi.nlm.nih.gov/books/NBK557523/)\n\n**Alcohol biomarkers.** Direct ethanol metabolites extend detection beyond breath or blood alcohol: urine EtG and EtS detect consumption within the past 5 days, blood PEth reflects intake over the past month, and hair EtG and FAEEs span a few months depending on hair length. PEth provides the highest sensitivity and specificity for recent (weeks) ethanol exposure.[23](https://www.sciencedirect.com/science/article/abs/pii/S0009912016300558)\n\n**Expanded panels and algorithms.** EHR-based deep learning screeners (SMART-AI and a deployed convolutional neural network OUD screener) and large language model sign-out systems extend detection to records-based prediction.[22](https://doi.org/10.1016/s2589-7500%2822%2900041-3) • [24](https://www.nature.com/articles/s41591-025-03603-z) • [25](https://jamanetwork-com.libproxy.ajou.ac.kr/journals/jamanetworkopen/fullarticle/2850599)\n\n## Applications\n\nIn primary care, the USPSTF recommends screening adults 18 and older (B recommendation) when accurate diagnosis, effective treatment, and appropriate care can be offered or referred; evidence is insufficient for adolescents.[1](https://jamanetwork.com/journals/jama/fullarticle/2766873) A 2024 systematic review of 33 emergency department studies found six alcohol tools or thresholds with both sensitivity and specificity of at least 83%, with AUDIT ≥8 and RAPS ≥1 having the highest sensitivities at 95%.[16](https://intjem.biomedcentral.com/articles/10.1186/s12245-024-00616-2) Federal workplace testing (DHHS) mandates a five-drug panel: amphetamines, cannabinoids, cocaine, opiates, and phencyclidine, with confirmation required before action.[8](https://www.mayoclinicproceedings.org/article/s0025-6196%2811%2961120-8/fulltext) • [18](https://www.mayoclinicproceedings.org/article/S0025-61961630825-4/fulltext) In addiction treatment, ASAM/ACMT consensus guides drug testing, while recommending that screening for substance use rely primarily on validated self-report tools.[26](https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/guidelines/drug-testing-2026/drug-testing-consensus-draft-v1-3-final-for-public-comment.pdf?sfvrsn=8747f7aa_3) In prenatal care, questionnaire accuracy is lower (sensitivity 0.37–0.76 for any prenatal drug use), and the 4P's Plus reached 0.87 sensitivity and 0.76 specificity in one study.[10](https://www.uspreventiveservicestaskforce.org/home/getfilebytoken/R3y9LSud52CGL8mG4wvxoT)\n\n## Limitations and alternatives\n\n**Interpretation limits.** A negative urine drug screen does not eliminate drug use as a cause of presenting signs and symptoms, and a positive screen does not mean the patient is addicted or under the influence.[7](https://www.ncbi.nlm.nih.gov/books/NBK557523/) Immunoassays cross-react with structurally similar substances, so results are presumptive positives until confirmed; documented interferents include ibuprofen, naproxen, efavirenz, and pantoprazole for cannabis assays, poppy seeds for opiates, sertraline and [oxaprozin](https://www.edgepedia.org/oxaprozin) for benzodiazepines, and venlafaxine, tramadol, and ketamine for PCP.[7](https://www.ncbi.nlm.nih.gov/books/NBK557523/) • [27](https://escholarship.org/content/qt30j0j2tr/qt30j0j2tr_noSplash_059fe3f5cf46e1e2e13074c932e02fa2.pdf) • [28](https://journals.sagepub.com/doi/10.1177/0897190015579611) The opiate screen, calibrated to morphine, does not detect fentanyl, methadone, or tramadol, and opiate assays vary widely in cross-reactivity with oxycodone and related compounds.[12](https://jlpm.amegroups.org/article/view/10561/html) • [9](https://myadlm.org/Science-and-Research/Academy-Guidance/Testing-for-Drugs-of-Misuse-to-Support-the-Emergency-Department) Immunoassays should not be relied on alone for synthetic cannabinoids.[29](https://www.sciencedirect.com/science/article/abs/pii/S1056871919304071) [Nitrite](https://www.edgepedia.org/nitrite) adulterants can oxidize the THC acid metabolite so it cannot be confirmed.[12](https://jlpm.amegroups.org/article/view/10561/html) At 11% adult prevalence, the positive predictive value of drug screening instruments is approximately 40%, meaning most positives are false.[10](https://www.uspreventiveservicestaskforce.org/home/getfilebytoken/R3y9LSud52CGL8mG4wvxoT)\n\n**Practical and ethical limits.** Observed urine collection is not recommended because it is perceived as degrading and stigmatizing.[26](https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/guidelines/drug-testing-2026/drug-testing-consensus-draft-v1-3-final-for-public-comment.pdf?sfvrsn=8747f7aa_3) False positives carry major implications for patient care, employment, and legal outcomes, so confirmatory testing should precede legal, forensic, academic, or employment decisions.[18](https://www.mayoclinicproceedings.org/article/S0025-61961630825-4/fulltext) Testing rarely changes management: in a 160-case Australian pediatric study of comprehensive screening (over 300 substances), management changed in only 3 cases.[7](https://www.ncbi.nlm.nih.gov/books/NBK557523/) ASAM/ACMT state that existing research has not demonstrated that routine or universal drug testing improves outcomes, and 27 counseling trials in screen-detected populations (\\( n = 8{,}705 \\)) showed no consistent effect on drug use at 3–12 months.[26](https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/guidelines/drug-testing-2026/drug-testing-consensus-draft-v1-3-final-for-public-comment.pdf?sfvrsn=8747f7aa_3) • [30](https://www.uspreventiveservicestaskforce.org/home/getfilebytoken/P2dj4AtxENrbjtFUSddmM3) [Laboratory](https://www.edgepedia.org/laboratory) testing is not a replacement for questionnaire screening because it detects only recent use, typically 1 to 4 days for urine, saliva, and blood.[2](https://www.ncbi.nlm.nih.gov/books/NBK565474/) Where definitive testing is feasible it adds real yield: in 883 patients on buprenorphine, immunoassay alone identified use in 81.0% versus 86.9% by mass spectrometry, and five high-risk substances would have gone unrecognized in 54.8% of patients tested by immunoassay alone.[31](https://link.springer.com/article/10.1186/s12954-025-01335-4)\n\n**Records-based prediction.** An AI OUD screener deployed in hospitals was non-inferior to usual care for addiction medicine consultations and was associated with 47% lower odds of 30-day readmission (OR 0.53, 95% CI 0.30–0.91).[24](https://www.nature.com/articles/s41591-025-03603-z) An LLM system trained on 83,553 urine drug tests predicted substance use patterns with AUC above 0.99 for 23 of 26 substances.[25](https://jamanetwork-com.libproxy.ajou.ac.kr/journals/jamanetworkopen/fullarticle/2850599) No substance has yet demonstrated AI success in both screening and management simultaneously, and implementation is shaped by stigma, data-sharing concerns, and 42 CFR Part 2 confidentiality requirements.[32](https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2026.1958597/full)\n\n## References\n\n1. [Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement](https://jamanetwork.com/journals/jama/fullarticle/2766873)\n2. [Substance Use Screening, Risk Assessment, and Use Disorder Diagnosis in Adults - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK565474/)\n3. [SBIRT Toolkit (Maryland Department of Health)](https://health.maryland.gov/pophealth/Documents/Local%20Health%20Department%20Billing%20Manual/PDF%20Manual/Section%20IV/SBIRT%20Toolkit.pdf)\n4. [Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II (Saunders et al., Addiction 1993)](https://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.1993.tb02093.x)\n5. [Screening for unhealthy use of alcohol and other drugs in primary care - UpToDate](https://www.uptodate.com/contents/screening-for-unhealthy-use-of-alcohol-and-other-drugs-in-primary-care/print)\n6. [Detecting Alcoholism: The CAGE Questionnaire (Ewing, JAMA 1984)](https://jamanetwork.com/journals/jama/fullarticle/394693)\n7. [Clinical Drug Testing - StatPearls - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK557523/)\n8. [fulltext (mayoclinicproceedings.org)](https://www.mayoclinicproceedings.org/article/s0025-6196%2811%2961120-8/fulltext)\n9. [ADLM guidance document on laboratory testing for drugs of misuse to support the emergency department](https://myadlm.org/Science-and-Research/Academy-Guidance/Testing-for-Drugs-of-Misuse-to-Support-the-Emergency-Department)\n10. [Screening for Unhealthy Drug Use: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force](https://www.uspreventiveservicestaskforce.org/home/getfilebytoken/R3y9LSud52CGL8mG4wvxoT)\n11. [Clinical Drug Testing in Primary Care (SAMHSA TAP)](https://library.samhsa.gov/sites/default/files/sma12-4668.pdf)\n12. [Modern drug testing in clinical laboratories: a narrative review of practical approaches and emerging technologies](https://jlpm.amegroups.org/article/view/10561/html)\n13. [Kristen Bush (1998). The AUDIT Alcohol Consumption Questions (AUDIT-C) An Effective Brief Screening Test for Problem Drinking. Archives of Internal Medicine.](https://doi.org/10.1001/archinte.158.16.1789)\n14. [The drug abuse screening test (Addictive Behaviors, 1982)](https://doi.org/10.1016/0306-4603%2882%2990005-3)\n15. [WHO ASSIST Working Group (2002). The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction.](https://doi.org/10.1046/j.1360-0443.2002.00185.x)\n16. [Screening for harmful substance use in emergency departments: a systematic review (Int J Emerg Med, 2024)](https://intjem.biomedcentral.com/articles/10.1186/s12245-024-00616-2)\n17. [Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool (NIDA)](https://nida.nih.gov/taps2)\n18. [Clinical Interpretation of Urine Drug Tests (Mayo Clinic Proceedings)](https://www.mayoclinicproceedings.org/article/S0025-61961630825-4/fulltext)\n19. [DEMMIE MAYFIELD, GAIL MCLEOD, PATRICIA HALL (1974). The CAGE Questionnaire: Validation of a New Alcoholism Screening Instrument. American Journal of Psychiatry.](https://doi.org/10.1176/ajp.131.10.1121)\n20. [Screening for alcohol problems in the emergency room: a rapid alcohol problems screen (Drug and Alcohol Dependence, 1995)](https://doi.org/10.1016/0376-8716%2895%2901199-4)\n21. [Jennifer McNeely and colleagues (2016). Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care Patients. Annals of Internal Medicine.](https://doi.org/10.7326/m16-0317)\n22. [Development and multimodal validation of a substance misuse algorithm for referral to treatment using artificial intelligence (SMART-AI): a retrospective deep learning study (The Lancet Digital Health, 2022)](https://doi.org/10.1016/s2589-7500%2822%2900041-3)\n23. [Alternative sampling strategies for the assessment of alcohol intake of living persons](https://www.sciencedirect.com/science/article/abs/pii/S0009912016300558)\n24. [Clinical implementation of AI-based screening for risk for opioid use disorder in hospitalized adults | Nature Medicine](https://www.nature.com/articles/s41591-025-03603-z)\n25. [Development and Implementation of an AI System for Generating Clinical Urine Drug Test Sign-Outs (JAMA Network Open)](https://jamanetwork-com.libproxy.ajou.ac.kr/journals/jamanetworkopen/fullarticle/2850599)\n26. [ASAM/ACMT Clinical Consensus Statement on Drug Testing in Substance Use Disorder Treatment (2026 public-comment draft)](https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/guidelines/drug-testing-2026/drug-testing-consensus-draft-v1-3-final-for-public-comment.pdf?sfvrsn=8747f7aa_3)\n27. [False-Positive Interferences of Common Urine Drug Screen Immunoassays: A Review](https://escholarship.org/content/qt30j0j2tr/qt30j0j2tr_noSplash_059fe3f5cf46e1e2e13074c932e02fa2.pdf)\n28. [What Can a Urine Drug Screening Immunoassay Really Tell Us?](https://journals.sagepub.com/doi/10.1177/0897190015579611)\n29. [Appraisal of state-of-the-art: Comparison of several immunoassays used in drugs of abuse screening](https://www.sciencedirect.com/science/article/abs/pii/S1056871919304071)\n30. [Screening for Unhealthy Drug Use in Primary Care in Adolescents and Adults, Including Pregnant Persons: Updated Systematic Review for the USPSTF](https://www.uspreventiveservicestaskforce.org/home/getfilebytoken/P2dj4AtxENrbjtFUSddmM3)\n31. [Harm reduction in the fourth wave of the opioid epidemic: definitive vs presumptive urine drug testing (Harm Reduction Journal)](https://link.springer.com/article/10.1186/s12954-025-01335-4)\n32. [Artificial intelligence for alcohol, opioid, and cannabis use disorders screening and management: a narrative review (Frontiers in Digital Health)](https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2026.1958597/full)\n33. [Mandatory guidelines for federal workplace drug testing programs authorized testing panels (federalregister.gov)](https://www.federalregister.gov/documents/2025/01/16/2025-00425/mandatory-guidelines-for-federal-workplace-drug-testing-programs-authorized-testing-panels)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Clinical assessment and procedures › Diagnosis and clinical assessment › Exercise and functional performance testing*\n\n*Initially written Sep 29, 2026 · Reviewed: Sep 30, 2026 · Edited: Sep 30, 2026 · Last review: Sep 30, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/substance-abuse-detection", "markdown_url": "https://www.edgepedia.org/substance-abuse-detection.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Substance abuse detection\", Edgepedia (EdgeChat), https://www.edgepedia.org/substance-abuse-detection. Edgepedia Community License 1.0.", "credit_md": "\"[Substance abuse detection](https://www.edgepedia.org/substance-abuse-detection)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/substance-abuse-detection](https://www.edgepedia.org/substance-abuse-detection). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Substance abuse detection\", Edgepedia (EdgeChat), https://www.edgepedia.org/substance-abuse-detection. Edgepedia Community License 1.0.", "speakable": "Substance abuse detection, also called drug abuse screening, is the set of clinical methods for identifying drug or alcohol misuse through questionnaires, laboratory testing, and electronic health record analysis." }